Core Viewpoint - Pfizer's upcoming earnings report is anticipated to show a significant decline in earnings and revenue compared to the previous year, raising investor interest [2][3]. Group 1: Stock Performance - Pfizer's stock increased by 1.16% to $24.51, outperforming the S&P 500's daily gain of 0.53% [1]. - Over the past month, Pfizer's stock has risen by 0.33%, which is below the Medical sector's gain of 2.87% and the S&P 500's gain of 0.71% [1]. Group 2: Earnings Estimates - Analysts expect Pfizer to report earnings of $0.68 per share on November 4, 2025, reflecting a year-over-year decline of 35.85% [2]. - The Zacks Consensus Estimate for Pfizer's revenue is projected at $16.81 billion, down 5.06% from the previous year [2]. Group 3: Full Year Projections - For the full year, the Zacks Consensus Estimates project earnings of $3.07 per share and revenue of $63.4 billion, indicating changes of -1.29% and -0.36% respectively from the prior year [3]. Group 4: Analyst Revisions and Rankings - Recent changes to analyst estimates for Pfizer are crucial as they reflect short-term business trends, with positive revisions indicating analyst optimism [3][4]. - Pfizer currently holds a Zacks Rank of 3 (Hold), with a 1.87% decline in the Zacks Consensus EPS estimate over the past month [5]. Group 5: Valuation Metrics - Pfizer's Forward P/E ratio is 7.88, significantly lower than the industry average of 14.5, suggesting it is trading at a discount [6]. - The PEG ratio for Pfizer is 0.8, compared to the industry average of 1.59, indicating a favorable valuation relative to expected earnings growth [6]. Group 6: Industry Context - The Large Cap Pharmaceuticals industry, part of the Medical sector, has a Zacks Industry Rank of 94, placing it in the top 39% of over 250 industries [7]. - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7].

Core Insights - The Zacks Rank system emphasizes earnings estimates and revisions to identify winning stocks, with value investing being a popular strategy for finding great stocks in various market conditions [1] - HF Sinclair (DINO) is highlighted as a stock to watch, currently holding a Zacks Rank of 2 (Buy) and an A grade for Value [2] Valuation Metrics - DINO has a Price-to-Book (P/B) ratio of 1.05, which is attractive compared to the industry average of 1.92. Over the past year, DINO's P/B has fluctuated between a high of 1.06 and a low of 0.53, with a median of 0.76 [3] - The Price-to-Sales (P/S) ratio for DINO is 0.35, which is also favorable when compared to the industry's average P/S of 0.39. This metric is preferred by some investors as it is less susceptible to manipulation [4] Investment Outlook - The combination of the above valuation metrics suggests that HF Sinclair is likely undervalued at present. Considering its strong earnings outlook, DINO stands out as one of the strongest value stocks in the market [5]

Core Viewpoint - Steel Dynamics (STLD) is set to report its financial results on October 20, 2025, with expectations of a significant increase in earnings per share (EPS) and revenue compared to the previous year [2][3]. Financial Performance - The anticipated EPS for the upcoming quarter is $2.66, reflecting a 29.76% increase year-over-year [2]. - Revenue is expected to reach $4.69 billion, indicating an 8.04% rise from the same quarter last year [2]. - For the entire year, the Zacks Consensus Estimates forecast an EPS of $8.9, which represents a decrease of 9.55% compared to the previous year, while revenue is projected at $18.22 billion, showing a growth of 3.88% [3]. Analyst Estimates - Recent changes in analyst estimates for Steel Dynamics are crucial, as upward revisions indicate positive sentiment regarding the company's business operations and profit generation capabilities [4]. - The Zacks Rank system, which evaluates these estimate changes, currently assigns Steel Dynamics a rank of 3 (Hold) [6]. Valuation Metrics - Steel Dynamics is trading at a Forward P/E ratio of 16.42, which is higher than the industry average of 13.51, suggesting a premium valuation [7]. - The company has a PEG ratio of 1.19, compared to the industry average of 0.81, indicating that Steel Dynamics is expected to grow at a faster rate than its peers [8]. Industry Context - The Steel - Producers industry, part of the Basic Materials sector, holds a Zacks Industry Rank of 96, placing it in the top 39% of over 250 industries [8].

Company Performance - Recursion Pharmaceuticals (RXRX) ended the recent trading session at $6.36, showing a -6.33% change from the previous day's closing price, which lagged behind the S&P 500's daily loss of 0.63% [1] - Over the past month, shares of Recursion Pharmaceuticals have appreciated by 44.16%, outperforming the Medical sector's gain of 3.09% and the S&P 500's gain of 0.92% [1] Upcoming Earnings - Analysts expect Recursion Pharmaceuticals to post earnings of -$0.35 per share in the upcoming earnings release, marking a year-over-year decline of 2.94% [2] - The current consensus estimate forecasts revenue to be $17.45 million, indicating a 33.11% decline compared to the same quarter of the previous year [2] Fiscal Year Projections - For the entire fiscal year, Zacks Consensus Estimates project earnings of -$1.5 per share and revenue of $72.38 million, representing changes of +11.24% and +23.02%, respectively, from the prior year [3] - Recent changes to analyst estimates for Recursion Pharmaceuticals reflect shifting dynamics in short-term business patterns, with positive estimate revisions indicating optimism about the business outlook [3] Zacks Rank and Industry Performance - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has a track record of exceeding expectations, with stocks rated 1 delivering an average annual return of +25% since 1988 [5] - Currently, Recursion Pharmaceuticals holds a Zacks Rank of 4 (Sell), with a 1.92% fall in the Zacks Consensus EPS estimate over the past month [5] - The Medical - Biomedical and Genetics industry, part of the Medical sector, has a Zacks Industry Rank of 84, placing it in the top 35% of all 250+ industries [6]

Company Overview - DocuSign (DOCU) closed at $67.12, down 1.16% from the previous trading session, underperforming the S&P 500, which lost 0.63% [1] - Over the past month, DocuSign shares have decreased by 19.65%, while the Computer and Technology sector gained 1.9% and the S&P 500 gained 0.92% [1] Upcoming Earnings - The upcoming earnings release is anticipated, with expected EPS of $0.92, reflecting a 2.22% increase from the prior-year quarter [2] - Revenue is projected to be $806.13 million, indicating a 6.8% increase compared to the same quarter last year [2] Annual Forecast - For the entire year, earnings are forecasted at $3.69 per share and revenue at $3.2 billion, representing increases of 3.94% and 7.34% respectively from the previous year [3] - Recent analyst estimate revisions suggest a positive outlook for the business [3] Analyst Ratings - The Zacks Rank system, which evaluates estimate changes, currently ranks DocuSign as 1 (Strong Buy), indicating a favorable investment opportunity [5] - Over the past month, the Zacks Consensus EPS estimate has increased by 2.13% [5] Valuation Metrics - DocuSign's Forward P/E ratio is 18.4, which is lower than the industry average of 29.25 [6] - The PEG ratio for DocuSign is 1.24, compared to the industry average of 1.98, suggesting a more attractive valuation relative to expected earnings growth [6] Industry Context - The Internet - Software industry, part of the Computer and Technology sector, holds a Zacks Industry Rank of 62, placing it in the top 26% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Core Insights - Robinhood Markets, Inc. closed at $131.44, down 2.02% from the previous session, underperforming the S&P 500, which fell 0.63% [1] - Over the past month, Robinhood's shares have increased by 13.07%, outperforming the Finance sector's decline of 0.83% and the S&P 500's gain of 0.92% [1] Earnings Expectations - The upcoming earnings report on November 5, 2025, is projected to show earnings of $0.49 per share, reflecting a year-over-year growth of 188.24% [2] - Quarterly revenue is expected to reach $1.16 billion, an increase of 81.66% from the same period last year [2] - For the full year, earnings are estimated at $1.76 per share and revenue at $4.17 billion, indicating growth of 61.47% and 41.29% respectively [3] Analyst Estimates and Stock Performance - Recent changes in analyst estimates for Robinhood are crucial as they often indicate shifts in near-term business trends [4] - Positive estimate revisions are interpreted as favorable for the business outlook [4] - The Zacks Rank system, which evaluates these estimate changes, currently rates Robinhood as 1 (Strong Buy), with a historical average annual return of +25% for such stocks since 1988 [6] Valuation Metrics - Robinhood is trading at a Forward P/E ratio of 76.29, significantly higher than the industry average of 16.22, suggesting a premium valuation [7] - The company's PEG ratio stands at 3.54, compared to the Financial - Investment Bank industry's average of 1.4 [8] - The Financial - Investment Bank industry is ranked 32 in the Zacks Industry Rank, placing it in the top 13% of over 250 industries [8]

Company Performance - UiPath's stock closed at $15.93, down 4.55% from the previous trading session, which was less than the S&P 500's loss of 0.63% [1] - Over the past month, UiPath's shares gained 41.2%, outperforming the Computer and Technology sector's gain of 1.9% and the S&P 500's gain of 0.92% [1] Upcoming Earnings - The upcoming earnings disclosure is highly anticipated, with projected earnings per share (EPS) of $0.14, reflecting a 27.27% increase year-over-year [2] - Quarterly revenue is estimated at $392.62 million, up 10.71% from the same period last year [2] Fiscal Year Estimates - For the entire fiscal year, earnings are projected at $0.65 per share and revenue at $1.57 billion, indicating increases of 22.64% and 10.07% respectively from the previous year [3] Analyst Forecasts - Recent revisions to analyst forecasts for UiPath are important as they indicate changing business trends, with positive revisions reflecting analysts' confidence in the company's performance [4] Zacks Rank and Valuation - UiPath currently holds a Zacks Rank of 1 (Strong Buy), with a proven track record of outperformance, as 1 stocks have returned an average of 25% annually since 1988 [6] - The Forward P/E ratio for UiPath is 25.74, which is a discount compared to the industry average of 29.25, and the PEG ratio is 1.07, compared to the industry average of 1.98 [7] Industry Context - The Internet - Software industry, part of the Computer and Technology sector, has a Zacks Industry Rank of 62, placing it in the top 26% of over 250 industries [8]

Company Overview - Strategy (MSTR) closed at $300.67, down 4.69% from the previous trading session, underperforming the S&P 500 which lost 0.16% [1] - The stock has decreased by 3.76% over the past month, compared to the Finance sector's loss of 1.81% and the S&P 500's gain of 1.14% [1] Earnings Expectations - The upcoming earnings report is scheduled for October 30, 2025, with projected earnings per share (EPS) of -$0.11, reflecting a 92.95% increase from the same quarter last year [2] - Quarterly revenue is expected to be $118.2 million, up 1.84% from the year-ago period [2] Annual Forecast - For the entire year, the Zacks Consensus Estimates forecast an EPS of -$15.73 and revenue of $466.75 million, indicating changes of -134.08% and +0.71% respectively compared to the previous year [3] Analyst Revisions - Recent revisions to analyst forecasts for Strategy are important as they reflect shifting business dynamics, with positive revisions indicating analysts' confidence in performance and profit potential [4] Share Price Momentum - Research shows that estimate revisions correlate with near-term share price momentum, and investors can utilize the Zacks Rank for actionable insights [5] Zacks Rank System - The Zacks Rank system ranges from 1 (Strong Buy) to 5 (Strong Sell), with a historical average annual return of +25% for 1 rated stocks since 1988 [6] - Currently, Strategy holds a Zacks Rank of 3 (Hold) [6] Industry Context - The Financial - Miscellaneous Services industry, part of the Finance sector, has a Zacks Industry Rank of 95, placing it in the top 39% of over 250 industries [7] - The top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Group 1 - Super Group (SGHC) Limited's stock decreased by 3.77% to $13.00, underperforming the S&P 500's daily loss of 0.16% [1] - Over the past month, shares of Super Group (SGHC) Limited increased by 6.46%, outperforming the Consumer Discretionary sector's decline of 4.43% and the S&P 500's gain of 1.14% [1] Group 2 - Super Group (SGHC) Limited is expected to report earnings of $0.14 per share, reflecting a year-over-year growth of 55.56%, with projected revenue of $529 million, a 19.48% increase compared to the previous year [2] - For the entire fiscal year, earnings are projected at $0.46 per share and revenue at $2.17 billion, indicating increases of 35.29% and 18.13% respectively from the prior year [3] Group 3 - Recent changes to analyst estimates for Super Group (SGHC) Limited indicate positive sentiment regarding the company's business operations and profit generation capabilities [4] - The Zacks Rank system, which assesses estimate changes, currently ranks Super Group (SGHC) Limited as 2 (Buy), with a 27.78% upward shift in the consensus EPS estimate over the past month [6] Group 4 - Super Group (SGHC) Limited has a Forward P/E ratio of 29.37, which is higher than the industry average Forward P/E of 21.62 [7] - The Gaming industry, part of the Consumer Discretionary sector, holds a Zacks Industry Rank of 55, placing it in the top 23% of over 250 industries [7]

Company Performance - Moderna's stock closed at $26.25, reflecting a -1.83% change from the previous day, underperforming the S&P 500's daily loss of 0.16% [1] - Over the past month, Moderna's stock has increased by 11.98%, outperforming the Medical sector's gain of 1.54% and the S&P 500's gain of 1.14% [1] Earnings Forecast - The upcoming earnings report for Moderna is expected to show an EPS of -$1.99, representing a significant 6733.33% decline from the same quarter last year [2] - Revenue is forecasted to be $861.08 million, indicating a 53.76% decrease compared to the same quarter of the previous year [2] - For the full year, earnings are projected at -$9.62 per share and revenue at $1.88 billion, reflecting changes of -8.46% and -41.8% respectively from the prior year [3] Analyst Revisions - Recent revisions to analyst forecasts for Moderna are crucial as they reflect short-term business trends, with upward revisions indicating analyst optimism regarding the company's profitability [4] - The Zacks Rank system, which incorporates estimate changes, has a strong track record of outperforming, with stocks rated 1 producing an average annual return of +25% since 1988 [6] Industry Context - The Medical - Biomedical and Genetics industry, part of the Medical sector, currently holds a Zacks Industry Rank of 94, placing it in the top 39% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]